Wellysis Corp. announced that it has issued redeemable convertible preferred stocks for gross proceeds of KRW 5,000,000,000 in a round of funding on May 30, 2022. The transaction included participation from Access Bio, Inc.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
6,850 KRW | -2.28% | -1.30% | -23.63% |
2023 | Access Bio, Inc. acquired an unknown minority stake in CuraPatient Inc. | CI |
2023 | Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022. | CI |
1st Jan change | Capi. | |
---|---|---|
-23.63% | 17Cr | |
-3.17% | 821.51Cr | |
+6.89% | 571.74Cr | |
+31.98% | 567.18Cr | |
-10.03% | 411.13Cr | |
-59.94% | 268.39Cr | |
+11.23% | 267.87Cr | |
-5.50% | 237.39Cr | |
+18.91% | 206Cr | |
-7.56% | 180.32Cr |
- Stock Market
- Equities
- A950130 Stock
- News Access Bio, Inc.
- Wellysis announced that it has received KRW 5 billion in funding from Access Bio, Inc.